Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.

Bergman J, Burman J, Gilthorpe JD, Zetterberg H, Jiltsova E, Bergenheim T, Svenningsson A.

Neurology. 2018 Oct 10. pii: 10.1212/WNL.0000000000006500. doi: 10.1212/WNL.0000000000006500. [Epub ahead of print]

PMID:
30305449
2.

Population-based cohort study on the epidemiology of acute appendicitis in children in Sweden in 1987-2013.

Almström M, Svensson JF, Svenningsson A, Hagel E, Wester T.

BJS Open. 2018 Apr 19;2(3):142-150. doi: 10.1002/bjs5.52. eCollection 2018 Jun.

3.

Maternal risk factors and perinatal characteristics of anorectal malformations.

Svenningsson A, Gunnarsdottir A, Wester T.

J Pediatr Surg. 2018 Nov;53(11):2183-2188. doi: 10.1016/j.jpedsurg.2018.04.021. Epub 2018 Apr 17.

PMID:
29907315
4.

Early central line-associated blood stream infections in children with cancer pose a risk for premature catheter removal.

Moell J, Svenningsson A, Af Sandeberg M, Larsson M, Heyman M, Harila-Saari A, Nilsson A.

Acta Paediatr. 2018 Jun 4. doi: 10.1111/apa.14432. [Epub ahead of print]

PMID:
29863780
5.

Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls.

de Flon P, Söderström L, Laurell K, Dring A, Sundström P, Gunnarsson M, Svenningsson A.

PLoS One. 2018 Feb 8;13(2):e0192516. doi: 10.1371/journal.pone.0192516. eCollection 2018.

6.

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.

Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F.

JAMA Neurol. 2018 Mar 1;75(3):320-327. doi: 10.1001/jamaneurol.2017.4011.

PMID:
29309484
7.

Cortico-juxtacortical and periventricular lesions and MS diagnostic criteria.

Svenningsson A, Ciccarelli O.

Neurology. 2017 Dec 5;89(23):2308-2309. doi: 10.1212/WNL.0000000000004725. Epub 2017 Nov 3. No abstract available.

PMID:
29101273
8.

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.

Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, Malmeström C, Svenningsson A, Olsson T, Piehl F, Blennow K, Lycke J.

Neurology. 2017 Nov 28;89(22):2230-2237. doi: 10.1212/WNL.0000000000004683. Epub 2017 Oct 27.

9.

In-hospital Surgical Delay Does Not Increase the Risk for Perforated Appendicitis in Children: A Single-center Retrospective Cohort Study.

Almström M, Svensson JF, Patkova B, Svenningsson A, Wester T.

Ann Surg. 2017 Mar;265(3):616-621. doi: 10.1097/SLA.0000000000001694.

PMID:
28169930
10.

Brain Parenchymal Fraction in Healthy Adults-A Systematic Review of the Literature.

Vågberg M, Granåsen G, Svenningsson A.

PLoS One. 2017 Jan 17;12(1):e0170018. doi: 10.1371/journal.pone.0170018. eCollection 2017. Review.

11.

How to minimize the risk for headache? A lumbar puncture practice questionnaire study.

Salzer J, Rajda C, Sundström P, Vågberg M, Vécsei L, Svenningsson A.

Ideggyogy Sz. 2016 Nov 30;69(11-12):397-402. doi: 10.18071/isz.69.0397.

PMID:
29733557
12.

Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS.

de Flon P, Laurell K, Söderström L, Gunnarsson M, Svenningsson A.

Mult Scler. 2017 Aug;23(9):1249-1257. doi: 10.1177/1352458516676643. Epub 2016 Oct 25.

PMID:
27780912
13.

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.

Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, Islam-Jakobsson P, Malmeström C, Axelsson M, Vågberg M, Sundström P, Lycke J, Piehl F, Svenningsson A.

Neurology. 2016 Nov 15;87(20):2074-2081. Epub 2016 Oct 19.

14.

Brain parenchymal fraction in an age-stratified healthy population - determined by MRI using manual segmentation and three automated segmentation methods.

Vågberg M, Ambarki K, Lindqvist T, Birgander R, Svenningsson A.

J Neuroradiol. 2016 Dec;43(6):384-391. doi: 10.1016/j.neurad.2016.08.002. Epub 2016 Oct 5.

15.

Population-based study shows that Hirschsprung disease does not have a negative impact on education and income.

Granström AL, Svenningsson A, Nordenskjöld A, Wester T.

Acta Paediatr. 2016 Dec;105(12):1508-1512. doi: 10.1111/apa.13594. Epub 2016 Oct 9.

PMID:
27639057
16.

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society.

Vågberg M, Axelsson M, Birgander R, Burman J, Cananau C, Forslin Y, Granberg T, Gunnarsson M, von Heijne A, Jönsson L, Karrenbauer VD, Larsson EM, Lindqvist T, Lycke J, Lönn L, Mentesidou E, Müller S, Nilsson P, Piehl F, Svenningsson A, Vrethem M, Wikström J.

Acta Neurol Scand. 2017 Jan;135(1):17-24. doi: 10.1111/ane.12667. Epub 2016 Aug 24. Review.

17.

Reply.

Alping P, Frisell T, Svenningsson A, Piehl F.

Ann Neurol. 2016 Nov;80(5):791-792. doi: 10.1002/ana.24767. Epub 2016 Sep 27. No abstract available.

PMID:
27553863
18.

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS.

Bergman J, Dring A, Zetterberg H, Blennow K, Norgren N, Gilthorpe J, Bergenheim T, Svenningsson A.

Neurol Neuroimmunol Neuroinflamm. 2016 Aug 2;3(5):e271. doi: 10.1212/NXI.0000000000000271. eCollection 2016 Oct.

19.

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.

de Flon P, Gunnarsson M, Laurell K, Söderström L, Birgander R, Lindqvist T, Krauss W, Dring A, Bergman J, Sundström P, Svenningsson A.

Neurology. 2016 Jul 12;87(2):141-7. doi: 10.1212/WNL.0000000000002832. Epub 2016 Jun 17.

PMID:
27316241
20.

Maternal Risk Factors and Perinatal Characteristics for Hirschsprung Disease.

Löf Granström A, Svenningsson A, Hagel E, Oddsberg J, Nordenskjöld A, Wester T.

Pediatrics. 2016 Jul;138(1). pii: e20154608. doi: 10.1542/peds.2015-4608. Epub 2016 Jun 15.

21.

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.

Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, Axelsson M, Malmeström C, Fink K, Lycke J, Svenningsson A, Piehl F.

Ann Neurol. 2016 Jun;79(6):950-8. doi: 10.1002/ana.24651. Epub 2016 Apr 20.

PMID:
27038238
22.

Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis.

Burman J, Svenningsson A.

J Neuroimmunol. 2016 Mar 15;292:40-4. doi: 10.1016/j.jneuroim.2016.01.008. Epub 2016 Jan 16.

PMID:
26943957
23.

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.

Al Nimer F, Elliott C, Bergman J, Khademi M, Dring AM, Aeinehband S, Bergenheim T, Romme Christensen J, Sellebjerg F, Svenningsson A, Linington C, Olsson T, Piehl F.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 7;3(1):e191. doi: 10.1212/NXI.0000000000000191. eCollection 2016 Feb.

24.

Rituximab in paediatric onset multiple sclerosis: a case series.

Salzer J, Lycke J, Wickström R, Naver H, Piehl F, Svenningsson A.

J Neurol. 2016 Feb;263(2):322-326. doi: 10.1007/s00415-015-7979-x. Epub 2015 Nov 24.

PMID:
26603152
25.

Vitamin D and axonal injury in multiple sclerosis.

Sandberg L, Biström M, Salzer J, Vågberg M, Svenningsson A, Sundström P.

Mult Scler. 2016 Jul;22(8):1027-31. doi: 10.1177/1352458515606986. Epub 2015 Oct 13.

PMID:
26462862
26.

Outcomes in infants with prenatally diagnosed gastroschisis and planned preterm delivery.

Mesas Burgos C, Svenningsson A, Vejde JH, Granholm T, Conner P.

Pediatr Surg Int. 2015 Nov;31(11):1047-53. doi: 10.1007/s00383-015-3795-8. Epub 2015 Sep 23.

PMID:
26399421
27.

Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden.

Wickström A, Sundström P, Wickström L, Dahle C, Vrethem M, Svenningsson A.

Mult Scler J Exp Transl Clin. 2015 Sep 22;1:2055217315608203. doi: 10.1177/2055217315608203. eCollection 2015 Jan-Dec.

28.

Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction.

Vågberg M, Norgren N, Dring A, Lindqvist T, Birgander R, Zetterberg H, Svenningsson A.

PLoS One. 2015 Aug 28;10(8):e0135886. doi: 10.1371/journal.pone.0135886. eCollection 2015.

29.

Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light.

Al Nimer F, Thelin E, Nyström H, Dring AM, Svenningsson A, Piehl F, Nelson DW, Bellander BM.

PLoS One. 2015 Jul 2;10(7):e0132177. doi: 10.1371/journal.pone.0132177. eCollection 2015.

30.

Increasing prevalence of multiple sclerosis in Västerbotten County of Sweden.

Svenningsson A, Salzer J, Vågberg M, Sundström P, Svenningsson A.

Acta Neurol Scand. 2015 Dec;132(6):389-94. doi: 10.1111/ane.12408. Epub 2015 Apr 10.

PMID:
25857351
31.

[Swedish neurologists--unusually disobedient when it comes to lumbar punctures].

Salzer J, Vågber M, Svenningsson A, Sunddström P.

Lakartidningen. 2014 Oct 1-7;111(40):1725. Swedish. No abstract available.

32.

Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness.

Penner IK, Sivertsdotter EC, Celius EG, Fuchs S, Schreiber K, Berkö S, Svenningsson A; TYNERGY trial investigators.

Front Neurol. 2015 Feb 23;6:18. doi: 10.3389/fneur.2015.00018. eCollection 2015.

33.

Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.

Svenningsson A, Bergman J, Dring A, Vågberg M, Birgander R, Lindqvist T, Gilthorpe J, Bergenheim T.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 26;2(2):e79. doi: 10.1212/NXI.0000000000000079. eCollection 2015 Apr.

34.

The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention.

Burman J, Svensson E, Fransson M, Loskog AS, Zetterberg H, Raininko R, Svenningsson A, Fagius J, Mangsbo SM.

J Neuroimmunol. 2014 Dec 15;277(1-2):153-9. doi: 10.1016/j.jneuroim.2014.10.005. Epub 2014 Oct 18.

PMID:
25457841
35.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Svenningsson A, Sundstrom P, Salzer J, Vagberg M.

Neurology. 2014 Nov 25;83(22):2099-100. doi: 10.1212/01.wnl.0000457455.74798.9a. No abstract available. Erratum in: Neurology. 2015 Feb 24;84(8):862.

PMID:
25422402
36.

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.

Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, Wattjes MP, Svenningsson A, Olsson T, Hartung HP, Hermsen D, Tumani H, Adams O, Kieseier BC.

Mult Scler. 2015 Jul;21(8):1036-44. doi: 10.1177/1352458514556296. Epub 2014 Nov 12.

PMID:
25392339
37.

Lumbar puncture preferences among Swedish neurologists.

Salzer J, Sundström P, Vågberg M, Svenningsson A.

Neurol Res. 2015 Jan;37(1):92-4. doi: 10.1179/1743132814Y.0000000442. Epub 2014 Sep 12.

PMID:
25213597
38.

Maternal and pregnancy characteristics and risk of infantile hypertrophic pyloric stenosis.

Svenningsson A, Svensson T, Akre O, Nordenskjöld A.

J Pediatr Surg. 2014 Aug;49(8):1226-31. doi: 10.1016/j.jpedsurg.2014.01.053. Epub 2014 Feb 10.

PMID:
25092081
39.

Age-dependent effects on the treatment response of natalizumab in MS patients.

Matell H, Lycke J, Svenningsson A, Holmén C, Khademi M, Hillert J, Olsson T, Piehl F.

Mult Scler. 2015 Jan;21(1):48-56. doi: 10.1177/1352458514536085. Epub 2014 May 27.

PMID:
24866201
40.

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, Vrethem M, Fredrikson S, Martin C, Sandstedt A, Uggla B, Lenhoff S, Johansson JE, Isaksson C, Hägglund H, Carlson K, Fagius J.

J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1116-21. doi: 10.1136/jnnp-2013-307207. Epub 2014 Feb 19.

PMID:
24554104
41.

Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.

Wickström A, Dahle C, Vrethem M, Svenningsson A.

Mult Scler. 2014 Jul;20(8):1095-101. doi: 10.1177/1352458513517590. Epub 2013 Dec 30.

PMID:
24378984
42.

Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP.

Press R, Askmark H, Svenningsson A, Andersen O, Axelson HW, Strömberg U, Wahlin A, Isaksson C, Johansson JE, Hägglund H.

J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):618-24. doi: 10.1136/jnnp-2013-306014. Epub 2013 Nov 21.

PMID:
24262917
43.

Supraumbilical incision with U-u umbilicoplasty for congenital duodenal atresia: the Stockholm experience.

Ghaffarpour N, Svensson PJ, Svenningsson A, Wester T, Mesas Burgos C.

J Pediatr Surg. 2013 Sep;48(9):1981-5. doi: 10.1016/j.jpedsurg.2013.06.028.

PMID:
24074679
44.

Plasma lipids, genetic variants near APOA1, and the risk of infantile hypertrophic pyloric stenosis.

Feenstra B, Geller F, Carstensen L, Romitti PA, Körberg IB, Bedell B, Krogh C, Fan R, Svenningsson A, Caggana M, Nordenskjöld A, Mills JL, Murray JC, Melbye M.

JAMA. 2013 Aug 21;310(7):714-21. doi: 10.1001/jama.2013.242978.

45.

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

Axelsson M, Malmeström C, Gunnarsson M, Zetterberg H, Sundström P, Lycke J, Svenningsson A.

Mult Scler. 2014 Jan;20(1):43-50. doi: 10.1177/1352458513490544. Epub 2013 May 23.

PMID:
23702432
46.

Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.

Khademi M, Dring AM, Gilthorpe JD, Wuolikainen A, Al Nimer F, Harris RA, Andersson M, Brundin L, Piehl F, Olsson T, Svenningsson A.

PLoS One. 2013 May 7;8(5):e63172. doi: 10.1371/journal.pone.0063172. Print 2013.

47.

Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.

Svenningsson A, Falk E, Celius EG, Fuchs S, Schreiber K, Berkö S, Sun J, Penner IK; Tynergy Trial Investigators.

PLoS One. 2013;8(3):e58643. doi: 10.1371/journal.pone.0058643. Epub 2013 Mar 21.

48.

Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies.

Svenningsson A, Dring AM, Fogdell-Hahn A, Jones I, Engdahl E, Lundkvist M, Brännström T, Gilthorpe JD.

Neurology. 2013 Mar 5;80(10):965-7. doi: 10.1212/WNL.0b013e3182840be3. Epub 2013 Feb 6. No abstract available.

PMID:
23390173
49.

Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.

Wickström A, Nyström J, Svenningsson A.

Mult Scler. 2013 Apr;19(5):622-30. doi: 10.1177/1352458512461391. Epub 2012 Sep 25.

PMID:
23012254
50.

Automated determination of brain parenchymal fraction in multiple sclerosis.

Vågberg M, Lindqvist T, Ambarki K, Warntjes JB, Sundström P, Birgander R, Svenningsson A.

AJNR Am J Neuroradiol. 2013 Mar;34(3):498-504. doi: 10.3174/ajnr.A3262. Epub 2012 Sep 13.

Supplemental Content

Loading ...
Support Center